Final-Program-ATS-2023-AP.vp

322

WEDNESDAY • MAY 24

502 Transitioning Patients With Pulmonary Arterial Hypertension From Parenteral Prostacyclin Therapy to Oral Selexipag: A Multi-center Retrospective Cohort Study/ B. Budhram, Calgary, Canada 503 A Mobile Health Intervention to Increase Physical Activity in Pulmonary Arterial Hypertension Is Associated With Alterations in Fatty Acid and Glucose Metabolism/ N.J. Shelburne, Nashville, TN 504 Hemodynamic Characteristics of Patients With Exercise Pulmonary Hypertension: Data From a Single Center-/ D.F. Condon, Boston, MA 505 The Safety and Efficacy of Inhaled Treprostinil in Patients With PH-ILD on Supplemental Oxygen: A Post-hoc Analysis of the INCREASE Study/ S. Sahay, Houston, TX 506 Electrocardiography (ECG) Findings in Clinical Trials of Pulmonary Arterial Hypertension/ J. Minhas, Philadelphia, PA 507 Validation Study for the Accuracy of Echocardiographic Indices of Right Ventricular Function in Pulmonary Hypertension/ H. Shima, Sapporo, Japan 508 A Comparison of Clinical and Real-world Defined Pulmonary Arterial Hypertension (PAH) Cohorts in Electronic Health Records (EHR) From the Mayo Clinic/ H.M. Dubrock, Rochester, MN 509 Pulmonary Blood Vessel Volume Is Distributed Into Smaller Vessels in Females Vs. Males/ S.P. Wright, Kelowna, Canada 510 Derivation and Validation of PrePHerred Score to Predict Precapillary Pulmonary Hypertension/ H. Deshwal, Morgantown, WV 511 Changes in the RC Time-constant in Response to Inhaled Nitric Oxide in People With Pulmonary Arterial Hypertension/ C.J. Dennis, Stanford, CA 512 Blood-derived Molecular Signature Could Predict PH in Patients With ILD/ D. Harrell, Sacramento, CA 513 Metabolic Profiling in Pulmonary Arterial Hypertension Associated With Congenital Heart Disease/ H. Zhang, Beijing, China 514 Pulmonary Vascular Pruning on Computed Tomography as a Non-invasive Indicator of Pulmonary Arterial Pressure and Compliance/ H. Robertson, Boston, MA 515 A Meta-analysis: Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Congenital Heart Disease (CHD) Receiving PAH Medication/ R.A. Krasuski, Durham, NC

916 The Role of a Pediatric Tracheostomy Committee: An Experience With a Dedicated Multi-disciplinary Counseling Committee at a Tertiary Referral Center/ F.D. Birru, Edmonton, Canada 917 Reducing Hospitalizations for Children on Chronic Invasive Mechanical Ventilation/ W.S. Stoudemire, Chapel Hill, NC 918 Continuous Positive Airway Pressure Weaning Guidelines Implementation Improves Respiratory Outcomes in Preterm Infants/ S. Mattikalli, Hershey, PA 919 Using the Electronic Patient Portal to Collect Patient-reported Data for Pediatric Asthma Management/ M.K. Ross, Los Angeles, CA 920 Project Breathe: Recurrent Admissions for Asthma Exacerbation. A Quality Improvement Project/ B. Prasanna Kumar, Buffalo, NY 921 Characterization of Pediatric Chronic Cough Via Electronic Medical Record Database/ K. Gavin, Kansas City, MO 922 Feasibility of Using Social Media to Provide Pediatric Pulmonary Patient Education/ N. Ba Sharahil, Madison, WI 923 Thc Effects on Diet and Exercise in Teenagers: Results From a Social Media Survey/ N. Malhotra, La Jolla, CA 924 Developing a Novel Pulmonary Assessment Module for Spinal Muscular Atrophy/ O.H. Mayer, Philadelphia, PA 925 Parental Depression, Medication Adherence, and Asthma Control Among Children in Low-Income Urban Households/ M.G. Mcinerney, Baltimore, MD

BASIC • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

D28

HOW CAN WE DO BETTER: EMERGING DIAGNOSTICS AND THERAPEUTICS IN PULMONARY VASCULAR DISEASE

8:00 a.m. - 10:00 a.m.

Walter E. Washington Convention Center Room 151 B (Street Level)

Poster Viewing

8:00-8:45 8:45-10:00

Discussion

Chairing: R. Souza, MD, PhD, Sao Paulo, Brazil S. Pugliese, MD, Philadelphia, PA

J. Minhas, MD, MS, MBBS, Philadelphia, PA D. Lachant, DO, ATSF, Rochester, NY 501 A Novel Approach to Clinical Change Endpoints: A Win Ratio Analysis of the INCREASE Trial/ S.D. Nathan, Falls Church, VA

516 Pharmacokinetic Profile of Imatinib Mesylate

Formulation (AER-901) Demonstrates Potential for Therapeutic Exposure Levels at Low Doses After Pulmonary Administration/ G.C. Burgess, Deerfield, IL

ATS 2023 • Washington, DC